Clinical trials: Anti-Thyroid Antibodies Disorder
Infertility, Female
Prevalence of Thyroid Dysfunction and Anti-thyroid Antibodies in Infertile Women
The study population will be divided into three groups: Group (A) consisting of 40 infertile women with either unexplained or anovulatory infertility with/without associated male factor of infertility, Group (B) consisting of 40…
- Trial name
- NCT03964779
- Testing
- Hormonal assay, Antibody assay
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Cairo University
Thyroid Cancer
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.
- Trial name
- NCT04612894
- Testing
- Camrelizumab and Apatinib, surgery, core needle biopsy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Fudan University
Graves Disease, Immunoglobulin
TSI and Its Relationship With Graves' Disease Relapse
The goal of this observational study is to determine the role of TSI, as well as clinical signs and thyroid function tests in predicting Graves' disease (GD) relapse after withdrawing anti thyroid drug (ATD).
- Conditions
- Graves Disease, Immunoglobulin, Anti-Thyroid Antibodies Disorder
- Trial name
- NCT05713097
- Testing
- TSI
- Where
- Vietnam
- Volunteers
- 352 people
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
Thyroid Cancer
Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
This study is a single-arm intervention study. Locally advanced differentiated thyroid carcinoma patients receive neoadjuvant therapy with Donafenib and PD-1 antibody Sintilimab and those who can undergo surgery after neoadjuvant…
- Trial name
- NCT06787911
- Testing
- Donafeib with Sintilimab
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Yu Wang
Thyroid Cancer
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
This is a patient pilot study testing the hypothesis that vemurafenib with the addition of KTN3379 can restore iodine incorporation in BRAF mutant (MUT), radioiodine-refractory (RAIR) thyroid cancer patients.
- Trial name
- NCT02456701
- Testing
- KTN3379, vemurafenib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Celldex Therapeutics
Thyroid Cancer
Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
The study is being conducted to evaluate the safety and efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody in subjects with advanced thyroid cancer.
- Trial name
- NCT04521348
- Testing
- multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Fudan University
Graves' Disease
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
Graves' disease is an autoimmune thyroid disorder in which autoantibodies against the thyroid-stimulating hormone receptor (TRAb) lead to excessive thyroid hormone production and systemic complications, as well as thyroid eye…
- Trial name
- NCT07261345
- Testing
- allogenic anti-CD19/BCMA CAR-T
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Shanghai Zhongshan Hospital
Thyroid Cancer
Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
This study is designed to evaluate the efficacy and safety of the combination of Toripalimab and Surufatinib for Locally Advanced Thyroid Cancer.
- Trial name
- NCT04524884
- Testing
- Surufatinib, Toripalimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fudan University
Thyroid Diseases, Pregnancy Related
Mapping Health-related Quality of Life in Pregnant Women With Thyroid Disease.
Natural thyroid function changes during pregnancy. In up to tens of percent of pregnant women, these changes can lead to pathological fluctuations in hormone and antibody production.
- Conditions
- Thyroid Diseases, Pregnancy Related, Quality of Life
- Trial name
- ThyPreQol2020 (NCT04167423)
- Where
- 7 sites in Czechia
- Volunteers
- 253 people
- Sponsor
- Value Outcomes Ltd.
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo